|
|
 Previous Article | Table of Contents | Next Article 
Protective Effect of a Single Interleukin-12 (IL-12) Predose Against the Toxicity of Subsequent Chronic IL-12 in Mice: Role of Cytokines and Glucocorticoids
Silvano Sacco,
Hubertine Heremans,
Berndt Echtenacher,
Wim A. Buurman,
Zoulikha Amraoui,
Michel Goldman, and
Pietro Ghezzi
From the Laboratory of Neuroimmunology, "Mario Negri" Institute for Pharmacological Research, Milano, Italy; Rega Institute, University of Leuven, Belgium; University of Regensburg, Regensburg, Germany; Department of Surgery, Limburg University, Maastricht, the Netherlands; and Laboratoire d'Immunologie Expérimentale, Université Libre de Bruxelles, Brussels, Belgium.
The mechanisms of interleukin-12 (IL-12) toxicity were studied in mice using a schedule (murine rIL-12, 400 ng/mouse, intraperitoneally [IP] once daily for 5 days) that markedly reduced body weight and food intake. On day 5, IL-12-treated mice had elevated serum and spleen IFN- and tumor necrosis factor (TNF). Serum sTNFR-P75 and corticosterone (CS) were also elevated. IL-12 toxicity was partially prevented by anti-IFN- antibodies or dexamethasone (DEX). A pre-dose of IL-12 (200 ng/mouse on day -14) completely prevented the toxicity of subsequent IL-12. The IL-12 predose also inhibited IL-12-induced IFN- levels, but did not modify IL-12-induced CS, TNF or sTNFR-P75. A protective effect was observed with a predose of lipopolysaccharide (LPS) or murine recombinant (r)IL-10. The protective effect of the IL-12 predose was reduced by coadministration of anti-IFN-, but a predose of murine rIFN- was not protective, suggesting that IFN- is necessary but not sufficient for the protective effect of IL-12. The IL-12 predose specifically protected against IL-12 toxicity and did not modify LPS toxicity. These data indicate that IL-12 can induce tolerance to its own toxicity, probably through a downregulation of IL-12-induced IFN- but independently of endogenous glucocorticoids. IFN-, and possibly IL-10, might be important in this tolerance.
Blood, Vol. 90 No. 11 (December 1), 1997:
pp. 4473-4479
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. N. MacGregor, Q. Li, A. E. Chang, T. M. Braun, D. P.M. Hughes, and K. T. McDonagh
Ex vivo Culture with Interleukin (IL)-12 Improves CD8+ T-Cell Adoptive Immunotherapy for Murine Leukemia Independent of IL-18 or IFN-{gamma} but Requires Perforin.
Cancer Res.,
May 1, 2006;
66(9):
4913 - 4921.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Sangro, G. Mazzolini, J. Ruiz, M. Herraiz, J. Quiroga, I. Herrero, A. Benito, J. Larrache, J. Pueyo, J. C. Subtil, et al.
Phase I Trial of Intratumoral Injection of an Adenovirus Encoding Interleukin-12 for Advanced Digestive Tumors
J. Clin. Oncol.,
April 15, 2004;
22(8):
1389 - 1397.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Melero, I. Gabari, I. Tirapu, A. Arina, G. Mazzolini, E. Baixeras, E. Feijoo, C. Alfaro, C. Qian, and J. Prieto
Anti-ICAM-2 Monoclonal Antibody Synergizes with Intratumor Gene Transfer of Interleukin-12 Inhibiting Activation-induced T-Cell Death
Clin. Cancer Res.,
September 1, 2003;
9(10):
3546 - 3554.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. A. Portielje, C. H. J. Lamers, W. H. J. Kruit, A. Sparreboom, R. L. H. Bolhuis, G. Stoter, C. Huber, and J. W. Gratama
Repeated Administrations of Interleukin (IL)-12 Are Associated with Persistently Elevated Plasma Levels of IL-10 and Declining IFN-{gamma}, Tumor Necrosis Factor-{alpha}, IL-6, and IL-8 Responses
Clin. Cancer Res.,
January 1, 2003;
9(1):
76 - 83.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Nakamura, T. Otani, Y. Ijiri, R. Motoda, M. Kurimoto, and K. Orita
IFN-{gamma}-Dependent and -Independent Mechanisms in Adverse Effects Caused by Concomitant Administration of IL-18 and IL-12
J. Immunol.,
March 15, 2000;
164(6):
3330 - 3336.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. A. Portielje, W. H. J. Kruit, M. Schuler, J. Beck, C. H. J. Lamers, G. Stoter, C. Huber, M. d. Boer-Dennert, A. Rakhit, R. L. H. Bolhuis, et al.
Phase I Study of Subcutaneously Administered Recombinant Human Interleukin 12 in Patients with Advanced Renal Cell Cancer
Clin. Cancer Res.,
December 1, 1999;
5(12):
3983 - 3989.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. A. Hirschowitz and R. G. Crystal
Adenovirus-Mediated Expression of Interleukin-12 Induces Natural Killer Cell Activity and Complements Adenovirus-Directed gp75 Treatment of Melanoma Lung Metastases
Am. J. Respir. Cell Mol. Biol.,
May 1, 1999;
20(5):
935 - 941.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. J. Robertson, C. Cameron, M. B. Atkins, M. S. Gordon, M. T. Lotze, M. L. Sherman, and J. Ritz
Immunological Effects of Interleukin 12 Administered by Bolus Intravenous Injection to Patients with Cancer
Clin. Cancer Res.,
January 1, 1999;
5(1):
9 - 16.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
